In signing an executive order aimed at reducing U.S. drug prices, President Donald Trump said some prices would be cut in half or more “almost immediately.” But the order is light on details of how the plan would be implemented.
President Joe Biden punctuated a campaign speech in Philadelphia with the phrase “a promise made and a promise kept,” when chronicling several actions his administration has taken. But in a few cases, he hasn’t kept the promise or he misleadingly described his accomplishments.
In a chaotic debate with plenty of crosstalk, there was also plenty to fact-check.
A Facebook user claims the cost of her insulin dropped 75% thanks to “Trumps Prescription Bill.” There has been no such legislation passed, and actions by the Trump administration aimed at lowering prescription drug costs have yet to take effect.
President Donald Trump accepted his party’s nomination in a speech filled with familiar falsehoods.
President Donald Trump recently signed executive orders that he says will reduce drug prices by 50% “and even greater, in certain instances.” That could happen for some individuals, but it remains to be seen how the orders will be implemented and whether they will result in such large reductions.
A Democratic TV ad attacks Sen. Susan Collins for voting twice “to allow drug companies to keep cheaper generic drugs off the market,” but omits the fact that Collins has supported bills intended to increase generic-drug competition and lower prescription costs.
For more than an hour, President Donald Trump presided over a cabinet meeting, reeling off numerous false or misleading claims.
One aim the president and Democratic 2020 challengers share is the desire to bring down the price of prescription drugs. But is that already happening, or are prices still climbing? The two parties disagree, and it depends on how they’re measuring drug prices.
Health and Human Services Secretary Alex Azar has described a new policy as “unleashing our Medicare Advantage plans to negotiate discounting on $12 billion of drugs.” Some patient advocacy groups have described the policy as one that “could erect barriers to care for cancer” and put “insurers in control of treatment decisions.” We’ll explain what the new policy entails.